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Cyclooxygenase-2 in Human and Experimental Ischemic
Proliferative Retinopathy
F. Sennlaub, MD, PhD; F. Valamanesh, MSc; A. Vazquez-Tello, PhD; A.M. El-Asrar, MD, PhD;
D. Checchin, MSc; S. Brault, MSc; F. Gobeil, PhD; M.H. Beauchamp, MSc; B. Mwaikambo, BSc;
Y. Courtois, PhD; K. Geboes, MD, PhD; D.R. Varma, MD, PhD; P. Lachapelle, PhD; H. Ong, PhD;
F. Behar-Cohen, MD, PhD; S. Chemtob, MD, PhD
Background—Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because
inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)–2 promotes tumor angio-
genesis, we investigated the role of COX-2 in ischemic proliferative retinopathy.
Methods and Results—We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the
murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2
but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its
prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of
thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3
stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36.
Conclusion—These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes.
(Circulation. 2003;108:198-204.)
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Intravitreal neovascularization, which characterizes diabeticretinopathy, retinopathy of prematurity, or retinal vein
occlusion, is a major cause of blindness.1 Retinal ischemia is
a common precursor to vitreal neovascularization in retinal
diseases2 and is associated with a local inflammatory re-
sponse in the ischemic retina.3 Early proinflammatory genes
are expressed in ischemic disorders. We have recently shown
that inducible NO synthase contributes to the development of
intravitreal neovascularization4 and to retinal apoptosis and
degeneration.5
Cyclooxygenase (COX)-2 is also an immediate-early gene
product of inflammation.6 Prostanoids are synthesized prin-
cipally via activities of COX-1 and COX-2. COX-1 is mostly
constitutive and is expressed in most tissues. COX-2 is
induced by cytokines, mitogens, and endotoxins, accounting
for elevated prostaglandin production during inflammation.6
COX-2 can be expressed developmentally and on ischemic
stimuli in retina.7 COX-2 exerts an angiogenic effects in
tumors8,9 and in corneal neovascularization.10 It has also been
shown that prostanoids, notably prostaglandin E2 (PGE2),
stabilize the hypoxia-inducible factor11 and stimulate expres-
sion of basic regulators of angiogenesis, including vascular
endothelial growth factor (VEGF) in tumor endothelium,8
resulting in endothelial cell proliferation.12 We hereby inves-
tigated the role of COX-2 in a nontumoral condition, namely
ischemic proliferative retinopathy, using human retinal tissue
and experimental proliferative ischemic retinopathy. Our
findings disclose an important role for this immediate-early
gene product in proliferative retinopathy mediated (at least in
part) by PGE2 mostly via prostaglandin E receptor 3 (EP3)
through a previously undescribed action involving
thrombospondin-1 (TSP-1) and CD36.
Methods
Human Samples
The eyes from 7 postmortem humans with diabetes mellitus, 4 eyes
from 4 postmortem humans with no history of diabetes or ocular
disease, and the ipsilateral eye from 1 subject with ocular ischemic
syndrome secondary to severe carotid artery obstruction (case 12)
were obtained.
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Animal Models of Ischemic Proliferative Retinopathy
All procedures were conducted in accordance with the Association
for Research in Vision and Ophthalmology’s statement, The Use of
Animals in Ophthalmic and Vision Research.
In the murine model, C57BL/6 mice at postnatal day (P) 7 were
exposed, with their mothers, for 5 days to hyperoxic conditions (75%
O2), inducing vaso-obliteration of the central retinal vasculature.13 At
P12, mice were returned to room air; extensive vitreal neovascular-
ization was present in all mice, with the maximum effect observed on
P17. Ischemic proliferative retinopathy was also reproduced in
Sprague-Dawley rats exposed to 7 cycles of hyperoxia (80% O2, 20.5
hours) and hypoxia (10% O2, 0.5 hours) with a gradual return to 80%
O2 over 3 hours, from P1 to P7.14 Thereafter, rats were returned to
room air, and neovascularization was evaluated at P12.
Mice and rats were anesthetized with an intraperitoneal injection
of a ketamine (100 mg/kg) and xylazine (15 mg/kg) solution and
intravitreally injected using glass capillaries (60 gauge). Right eyes
of mice were injected intravitreally at P13 and P15 with 0.5 L of
vehicle (50% polyethylene glycol [Sigma-Aldrich], 40% PBS, and
10% ethanol); 2, 10, or 50 mol/L of specific COX-2 inhibitor
o-(Acetoxyphenyl)hept-2-ynyl sulfide (APHS)15 (Calbiochem,
France Biochem) (n16/group); vehicle (90% 0.9% NaCl and 10%
ethanol); 2, 10, or 50 mol/L of the selective COX-1 inhibitor
SC-56016 (Calbiochem) (n16/group); or 0.3 mol/L 16,16-
dimethyl-PGE2 (Sigma-Aldrich), resulting in estimated effective
vitreal concentrations of drugs (estimated total eye volume of 10 L
based on spheric volume and volume-to-weight ratio calculation) of
0.2, 1, and 5 mol/L (APHS and SC-560) and 0.03 mol/L
(16,16-dimethyl-PGE2). Eyes were enucleated at P17 and subjected
to retinal histochemistry (n8) and intravitreal neovascularization
quantification (n8) (see below). Rat pups (n8 to 13/group) were
injected in the right eye at P7 and P9 with either 1 L of vehicle
(NaCl 0.9%) or the selective COX-2 inhibitor etodolac 40 mol/L16
(Sigma-Aldrich) with or without 16,16-dimethyl-PGE2 4 mol/L
(Cayman Chemicals), a specific EP2 or EP3 agonist, respectively,
butaprost 400 mol/L (Cayman Chemicals) or M&B28767 4
mol/L (Rhone-Poulenc Rorer),17 to obtain estimated effective
vitreal concentrations of drugs (estimated total eye volume of 40 L)
of 1 (etodolac), 0.1 (16,16-dimethyl-PGE2), 10 (butaprost), and 0.1
(M&B28767) mol/L; EP2 and EP3 receptor agonists were used
because antagonists are not readily available. Rats were euthanized
at P12 and retinas stained for endothelial cells and flat mounted (see
below).
Immunohistochemistry
Human and murine eyes were fixed in 4% paraformaldehyde and
embedded, sectioned (5 m), and deparaffinized. Sections were
stained using a heat-induced antigen retrieval and a 3-step avidin-
biotin complex technique using avidin–alkaline phosphatase or
avidin-FITC as previously described.4 Antibodies used were poly-
clonal COX-2 antibody (Biomol Laboratories and Cayman Chemical
Co), monoclonal EP3 antibody (generous donation by Exalpha
Biologicals), monoclonal glial fibrillary acidic protein (GFAP)
(Oncogene), and TRITC-conjugated lectin griffonia simplicifolia
(Sigma-Aldrich).
Cell Culture
Given the need for sufficient tissue quantities, primary astrocyte and
endothelial cell cultures were obtained for practical reasons from
neonatal porcine retinas; cells from this species respond to a variety
of stimuli implicated in ischemic retinopathies in the same manner as
that of rodent tissues.18,19 Neonatal porcine retinal astrocytes were
isolated as described for brain astrocytes.20 Cells of the third to
fourth passages were used. Cultures were 95% GFAP positive.
Monolayers (80% confluent) of astrocytes were incubated at 37°C
either under normoxic (95% air, 5% CO2) or hypoxic conditions (2%
O2, 5% CO2, 93% N2) for 24 hours. Subsequently, the medium was
changed and cells were incubated for 1 hour in the presence of APHS
(1 mol/L), etodolac (1 mol/L), SC-560 (0.2 mol/L), or etodolac
(1 mol/L) and SC-560 (0.2 mol/L); drug concentrations used were
equivalent to those estimated in vivo. PGE2 concentrations were
measured in the supernatant, and the cells were harvested for protein
quantification and Western blot analysis. The pH of the medium was
unchanged during 24-hour hypoxia. For endothelial cell culture,
newborn porcine neuroretinal microvessels were isolated as previ-
ously reported.18
Western Blot
Protein extraction of cells was performed as previously described.18
Rat retinas were pooled3,4 and membranous and cytosolic fractions
were separated as previously described.21 Antibodies used were
polyclonal anti–COX-2 (Cayman); polyclonal anti–COX-1 (Santa
Cruz Biotechnology); mouse monoclonal EP2, EP3, and EP4 (Exalpha
Biologicals); polyclonal anti-VEGF antibody (Chemicon); rat mono-
clonal anti–VEGF receptor (VEGFR)–2 (Chemicon); monoclonal
anti–TSP-1 (Oncogene); polyclonal purified anti-CD36; monoclonal
Subject Characteristics and Results of COX-2 Staining
Case No.
Age,
Sex
Type
of
DM
Duration
of DM,
y
Cause
of
Death
Death to
Enucleation,
h
COX-2
Expression
in NFL
Subjects with diabetes
1 52, M IDDM 14 Coronary artery disease 14 
2 68, M NIDDM 15 Intestinal ischemia 6 
3 75, F NIDDM 14 Coronary artery disease 17 
4 74, F NIDDM 10 Chronic obstructive pulmonary disease 12 
5 70, M NIDDM 20 Renal failure 9 
6 58, M NIDDM 16 Intracranial bleeding 10 
7 67, F NIDDM 18 Coronary artery disease 21 
Subjects without diabetes
8 37, F       Cardiogenic shock 12 
9 52, M       Colorectal cancer 17 
10 78, M       Chronic obstructive lung disease 17 
11 41, M       Road traffic accident 15 
12 41, M       Road traffic accident 17 
DM indicates diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; NIDDM, non–insulin-dependent
diabetes mellitus; NFL, nerve fiber layer; M, male; and F, female.
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anti-clathrin (Transduction Laboratories, BD Biosciences); monoclo-
nal anti–-actin (Novus Biological); and monoclonal GFAP (Onco-
gene). Western blots were performed on equal amounts of proteins as
described.18
PGE2 Radioimmunoassay
PGE2 concentrations in retinal tissue (n3 per group) and astrocyte
supernatant were determined as previously described.22
RNA Isolation and Reverse Transcription–
Polymerase Chain Reaction (PCR) Analysis
Retinal mRNA expression from whole retinal extracts (n3 per group) was
analyzed using reverse transcription–PCR (cycles below the saturating
conditions) as previously described.4 Oligonucleotide primers were the
following: for COX-2, antisense 5-GGAGAAGGCTTCCCAGCTTTTG-
3, and sense 5-GCAAATCCTTGCTGTTCCAATC-3, resulting in a
PCR product of 336 bp; for actin, antisense 5-GCTCATTGCC-
GATAGTGATGACCT-3, and sense 5-GGTGGGTATGGGT-
CAGAAGGA-3, resulting in a 630-bp PCR product.
Quantification of Vitreal Neovascularization and
Intraretinal Revascularization
Mouse eyes were paraffin embedded, cut sagitally (parallel to the
optic nerve), and stained with periodic acid-Schiff and Hemalun.
Vitreal neovascularization (vascular cell nuclei found on the vitreal
side of the inner limiting membrane) was counted by blinded
investigators as previously described.4 Neovascular nuclei were
absent in animals raised in room air. Intraretinal vasculature was
visualized on retinal flat mounts stained with TRITC-conjugated
lectin griffonia simplicifolia (Sigma-Aldrich),23 and the surface of
the capillary free area measured using a computerized image-analy-
sis system (Scion Image). In the rat model, intravitreal neovascular-
ization was evaluated by counting intravitreal neovascular tufts on
lectin-stained retinal flat mounts.
Statistical Analysis
Results are expressed as meanSEM. Statistical analyses were
performed using the Mann-Whitney test and ANOVA. Statistical
significance was set at P0.05.
Results
COX-2 Expression in Human Diabetic Retina
Patient characteristics are summarized in the Table. COX-2
immunoreactivity was observed in all eyes in the retinal
pigment epithelial cells, in the outer segment of the photore-
ceptors and to some degree in the inner plexiform layer (data
not shown). In all diabetic subjects, COX-2 immunoreactivity
was also detected in the nerve fiber layer (NFL) (Figure 1a,
cases 1 to 7); this COX-2 immunostaining was granular and
discontinuous. COX-2 immunolocalized mostly with GFAP
indicative of astrocytes (Figure 1c through 1e); similar results
were obtained using 2 different COX-2–specific antibodies
(see Methods). A comparable pattern was found in the eye of
a nondiabetic subject who had suffered from severe carotid
artery obstruction (case 12). In contrast, in the other nondia-
betic patients, COX-2 immunoreactivity was not observed in
the NFL (Figure 1b and 1f through 1h, cases 8 to 11).
COX-2 Expression and Localization, and
PGE2 Concentrations in Experimental
Ischemic Retinopathy
COX-2 expression is altered by ischemia in neural tissue.24
We explored the involvement of COX-2 in a murine model of
retinopathy of prematurity. Equivalent COX-2 mRNA ex-
pression was observed in room air and after hyperoxia
exposure at P12, P14, and P17 (Figure 2A). Immunolocaliza-
tion of COX-2 was studied in mouse retina and was found to
be similar to that in humans. In normoxic mice at P14, COX-2
protein was robustly expressed in retinal pigment epithelial
cells both in the outer photoreceptor segment and in the inner
plexiform layer (data not shown). In the post–hyperoxia-
exposed retinas, COX-2 expression was also detected in the
NFL at P14 (Figure 3a) predominantly in astrocytes (GFAP
positive) (Figure 3e and 3f).
COX-2 protein expression was evaluated in membrane
fractions of retina extracts from hyperoxia-exposed rats.
At the end of the hyperoxic period (P1 through P7), COX-2
immunoreactivity diminished and tended to increase in the
early hours after resuming exposure to room air (24 hours
after hyperoxia; Figure 2C). COX-1 exhibited the reverse
pattern, and consequently whole retina concentrations of
PGE2, a mediator involved in angiogenesis,25 were unal-
tered during the posthyperoxia period (Figure 2B); al-
though this does not exclude a local paracrine effect of this
autacoid. Consistent with these observations, primary ret-
inal astrocyte cultures exposed for 24 hours to relative
hypoxia (2% O2, 5% CO2, 93%) exhibited increased
COX-2 expression (Figure 2D) and PGE2 levels (Figure
2E) compared with those in normoxia (95% air, 5% CO2),
whereas COX-1 expression remained steady. Specific
COX-2 inhibitors, APHS and etodolac, markedly dimin-
Figure 1. COX-2 immunohistochemistry on human retinas of
diabetic (a and c through e) and nondiabetic (b and f through h)
subjects. Shown is colocalization of GFAP and COX-2 in nondi-
abetic (f through h) and diabetic (c through e) eyes. Panel
heights are 240 m (a and b) and 90 m (c through h). NFL
indicates nerve fiber layer; INL and ONL, inner nuclear layer and
outer nuclear layer, respectively.
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ished PGE2 levels, whereas COX-1–selective SC-560 only
caused a small decrease in PGE2 concentrations (Figure
2E) even at highest dose tested (5 mol/L), suggesting a
dominant role for COX-2 in PGE2 generation during
hypoxia.
In age-adjusted normoxic whole retinas, COX-1 and -2
expression did not change. Immunolocalization of COX-2 in
rat retina was similar to that observed in mouse (data not
shown).
COX Inhibition in Ischemic
Proliferative Retinopathy
The impact of COX inhibition on neovascularization was
tested using specific COX-2 (APHS and etodolac) and
COX-1 (SC-560) inhibitors; concentrations corresponded to
effective ones on astrocyte PGE2 levels (Figure 2E). In vivo,
posthyperoxia administration of the preferential COX-2 in-
hibitor APHS did not affect the degree of capillary-free area
or the intraretinal revascularization of the ischemic retina
studied 4 days after the first dose (P17) (Figure 4A and 4B).
However, intravitreal neovascularization (revealed by intrav-
itreal vascular nuclear counts) was dose-dependently dimin-
ished by APHS, whereas the selective COX-1 inhibitor
SC-56015 was ineffective (Figure 4C). PGE2 levels in whole
retina were reduced by 65% 24 hours after APHS treatment.
Moreover, intravitreal injection of PGE2 after the hyperoxic
period led to a significant (albeit mild) increase in intravitreal
neovascularization.
To confirm the role of COX-2 in retinal neovasculariza-
tion, its involvement was tested using a distinct selective
COX-2 inhibitor, etodolac,16 as well as a different species, the
rat model of ischemic proliferative retinopathy. Etodolac
caused a marked decrease in retinal neovascularization (stud-
ied at 5 days after the first injection) (Figure 5A and 5B). This
effect was reversed by PGE2.
To further explore the PGE2 pathway, PGE2 receptor
expression and its changes during the posthyperoxia period
were studied. Hyperoxia caused a slight decrease in EP4
(Figure 5C), whereas EP1 was undetectable (not shown). In
contrast, EP2 and to a greater extent EP3 receptor expres-
sion was significantly decreased by hyperoxia and in-
creased substantially during the posthyperoxia period (Fig-
ure 5C), coincidental with COX-2 changes (Figure 2C).
Moreover, addition of the EP2 agonist butaprost and the
EP3 agonist M&B2876717 reversed in part or exacerbated
the inhibitory effects of etodolac on retinal neovascular-
ization. EP3 receptor expression also increased in the same
phase in that of the murine eye, predominantly localized in
retinal endothelium (lectin griffonia–positive cells) (Fig-
ure 3f through 3h).
Figure 2. COX expression and PGE2 levels in retina of models
of ischemic proliferative retinopathy. Mice were exposed to 75%
O2 from P5 to P12, and rats to cycling O2 concentrations of
10% to 80% from P1 to P7. A, COX-2 mRNA expression in
mice. B, Retinal PGE2 concentrations in mice. C, COX-1 and -2
immunoreactivity in rats. D, COX-1 and -2 immunoreactivity in
cultured astrocytes in 21% or 2% O2 for 24 hours (see Meth-
ods). E, PGE2 levels in media of cultured astrocytes in normoxic
(20% O2) and hypoxic (2% O2) conditions with or without 1-hour
treatment with APHS (1 mol/L), etodolac (1 mol/L), and/or
SC-560 (0.2 mol/L). Histogram bar values are meanSEM.
*P0.5 compared with other corresponding values.
Figure 3. COX-2 (a through c, e) and EP3 (f and h) immunohis-
tochemistry of posthyperoxic (ischemic; a, c through e, f
through h) and normoxic mouse retina at P14 (as described in
Figure 2); shown are GFAP immunoreactivity (astrocyte marker,
d) and lectin griffonia simplicifolia labeling (endothelium marker,
g). Panel height, 130 m (a and b); 95 m (c through e); and 48
m (f through h). NFL indicates nerve fiber layer; INL and IPL,
inner nuclear layer and inner plexiform layer, respectively.
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Effects of COX-2 Inhibition and EP3 Stimulation
on Expression of Modulators of Angiogenesis
Involvement of COX-2 and EP3 on pro- and antiangiogenic
factors, notably VEGF, VEGFR2, TSP-1, and CD36,26,27 was
studied in retina of models of proliferative retinopathy.
Twenty-four hours after removal from hyperoxia, there was
an increase in TSP-1 expression. The COX-2 inhibitor
etodolac induced a substantial increase in both TSP-1 and
CD36, and addition of the EP3 agonist M&B28767 reversed
this effect. In contrast, effects of COX-2 on neovasculariza-
tion could not be explained by the VEGF pathway; VEGF
expression, although as anticipated it increased during the
posthyperoxic period, was marginally affected by etodolac
and M&B28767 (Figure 6A), and VEGFR2 remained unal-
tered. In accord with in vivo observations, etodolac caused a
slight increase in TSP-1 expression in neuroretinovascular
endothelial cells, and this effect was reversed by M&B28767
(Figure 6B), consistent with EP3 expression on retinal endo-
thelium (Figure 3f).
Discussion
Inflammatory mediators contribute to the pathogenesis of
ischemic proliferative retinopathy.3,4 In a related manner,
COX-2 has been implicated in angiogenesis, especially of
tumors.6 Although COX inhibition diminishes retinal neovas-
cularization in ischemic models,28 the specific involvement of
COX-2 and the identity of its products in this process have
not been elucidated. Our findings disclose an important role
for this immediate-early gene product in proliferative retinop-
athy. COX-2 expression increased coincidentally with that of
EP2 and EP3 during the ischemic (posthyperoxic in models)
phase associated with proliferation, particularly localized,
respectively, in astrocytes and in endothelial cells of the NFL.
COX-2 contributed to the preretinal neovascularization in
different models of ischemic retinopathies, which seems to be
mediated by PGE2 acting via EP2 and to a greater extent EP3
receptors, and these in turn modulate the antiangiogenic
factor TSP-1 and its receptor CD36 on target endothelial
cells.
COX-2 was abundantly present in synaptic regions of the
retina of all species studied (human, mouse, and rat) as seen
in the brain.29 In addition, COX-2 was induced in the NFL of
retinas of humans with diabetes and vascular obstruction
(case 12) and in animals after hyperoxia, hence during
hypoxic-ischemic phases; in these instances, COX-2 was
mostly induced in astrocytes (but also in endothelium [Figure
Figure 4. Effects of COX-1 and -2 inhibition on retinal vascular
density (A and B) and intravitreal neovascularization in murine
model of ischemic proliferative retinopathy at P17. Animals were
prepared as described in Methods and injected intravitreally at
P13 and at P15 with APHS, SC560, or PGE2; estimated effective
vitreal concentrations are indicated.15,16 B, Arrows on retinal flat
mounts in panels 1 and 2 point to avascular zone and in panel 3
to intravitreal neovessels. Panel heights, 5 mm (B1 and B2) and
240 m (B3 and B4). Values in histograms are meanSEM;
*P0.01 compared with vehicle; †P0.05 compared with other
corresponding values for APHS (ANOVA).
Figure 5. Effects of COX-2 inhibitor etodolac and PGE2 analogs
in rat model of ischemic proliferative retinopathy. Rats were
exposed to hyperoxia from P1 through P7 (as defined in Figure
2 legend) and injected intravitreally on P7 and P9 with etodolac
with or without PGE2, butaprost, or M&B28767 (M&B) for esti-
mated effective16,17 vitreal concentrations, respectively, of 1, 0.1,
10, and 0.1 mol/L; retinas were isolated on P12. A, Retinal flat
mounts; 1, vehicle treated; 2, etodolac treated; 3,
etodolacPGE2 treated; and 4, etodolacM&B28767 treated.
Arrows indicate neovascular buds. Panel height, 1.1 mm. B,
EP2, EP3, and EP4 protein expression in retinas. Values in histo-
grams are meanSEM; *P0.05 compared with all other corre-
sponding values.
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6B]) and seemed to account for a large portion of PGE2
generation (Figure 2E). Consistent with the time-dependent
and propitious localization of COX-2, molecularly distinct
inhibitors of this enzyme (APHS and etodolac15,16) markedly
diminished preretinal neovascularization (Figures 4 and 5),
whereas COX-1 inhibition was ineffective. Moreover, admin-
istration of the well-recognized proangiogenic COX product
PGE22,5,10 (Figure 4) reversed the antiangiogenic effects of
COX-2 inhibitors in the retina (Figures 4 and 5). In view of
the significant COX-1 expression even during the hypoxic
phase (Figure 2C and 2D), one would have predicted some
effect of COX-1 inhibition on neovascularization. However,
COX-2 seems to be coregulated and biochemically coupled
with the inducible gene product microsomal PGE2 synthase, a
dominant generator of PGE2 under certain inflammatory
conditions,30 whereas COX-1 appears to be mostly coupled to
the constitutive cytosolic PGE2 synthase. This inference may
explain at least in part the differences observed between
COX-1 and COX-2 inhibitors. Of note, we found augmented
microsomal PGE2 synthase during the posthyperoxic period
(data not shown) and, accordingly, a major role for COX-2 in
PGE2 generation during hypoxia (Figure 2E).
The angiogenic effect of PGE2 seemed to be mediated via
its EP2 and especially EP3 receptors, as specific stimulation of
these receptors reversed the effects of etodolac on neovascu-
larization (Figure 5); selective antagonists to these receptors
are not readily available. Of interest, EP2 and EP3 have
recently been reported to participate in colorectal tumor
angiogenesis,31,32 and these effects may be mediated via
VEGF, a major factor in ischemic proliferative retinopathy26;
similarly, COX-2 inhibition downregulated VEGF in colon
tumor endothelial cells.8 But in other endothelial cells (breast
tumor and cornea), COX-2 inhibition affected the basic
fibroblast growth factor pathway,9 which plays a minor role
in ischemic proliferative retinopathy.33 Endothelial cells are
not homogeneous throughout tissues, and in retina the effect
of COX-2 inhibition was largely unrelated to the VEGF
pathway (Figure 6). Thus, COX-2 inhibition may interfere
with pathways that are independent of specific growth fac-
tors. Plausible candidate pathways are through TSP-1 and its
receptor CD36, which inhibit angiogenesis via p38 mitogen-
activated protein kinase and caspase 3.34 This conjecture is
supported by an upregulation of TSP-1 and CD36 by COX-2
inhibitor and reversal of these effects by EP3 stimulation
(Figure 6). Although a prostaglandin D2 metabolite–depen-
dent peroxisome proliferator-activated receptor-–mediated
induction of TSP-1 and CD36 has been documented,35 an
EP3-evoked one as we observed (Figure 6) discloses a
previously undescribed mode of regulation of these antian-
giogenic factors.
In summary, COX-2 contributes markedly to preretinal
neovascularization in ischemic retinopathies, and this effect
seems to be PGE2 mediated mostly via EP3 receptors impli-
cating a new interaction through TSP-1 and CD36. Results
suggest that selective COX-2 inhibitors could be used for the
control of pathological vitreal neovascularization in ischemic
proliferative retinopathy. More specifically, EP3 (and possi-
bly EP2) antagonists may be more selective by sparing the
potentially physiologically desirable effects of the various
COX-2 products.
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